Kiniksa Pharmaceuticals International Management
Management criteria checks 4/4
Kiniksa Pharmaceuticals International's CEO is Sanj Patel, appointed in Jul 2015, has a tenure of 9.42 years. total yearly compensation is $5.30M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 2.38% of the company’s shares, worth $35.32M. The average tenure of the management team and the board of directors is 3.9 years and 7.4 years respectively.
Key information
Sanj Patel
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 16.3% |
| CEO tenure | 9.4yrs |
| CEO ownership | 2.4% |
| Management average tenure | 3.9yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Compensation vs Market: Sanj's total compensation ($USD5.30M) is about average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Sanj's compensation has been consistent with company performance over the past year.
CEO
Sanj Patel (55 yo)
9.4yrs
Tenure
US$5,297,067
Compensation
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.4yrs | US$5.30m | 2.38% $ 35.3m | |
| Senior VP & COO | 2.9yrs | US$1.75m | 0.13% $ 2.0m | |
| Senior VP & Chief Medical Officer | 8.3yrs | US$1.79m | 0.072% $ 1.1m | |
| Senior VP & CFO | 4yrs | no data | 0.032% $ 472.7k | |
| Chief Accounting Officer & Group VP of Finance | 4.8yrs | no data | 0.037% $ 546.2k | |
| Senior Vice President of Technical Operations | 3.9yrs | no data | no data | |
| Senior VP & Chief Compliance Officer | 3.7yrs | no data | no data | |
| SVP, General Counsel & Secretary | 3.9yrs | no data | no data | |
| Executive Vice President of Corporate Affairs | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 4yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | 2.9yrs | no data | 0.030% $ 447.5k | |
| Chief Business Officer | less than a year | no data | no data |
3.9yrs
Average Tenure
51.5yo
Average Age
Experienced Management: KNSA's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.4yrs | US$5.30m | 2.38% $ 35.3m | |
| Independent Director | 6.8yrs | US$362.66k | 0.013% $ 193.0k | |
| Lead Independent Director | 9.2yrs | US$411.06k | 0.040% $ 588.6k | |
| Independent Director | 8yrs | US$380.36k | 0.013% $ 193.0k | |
| Independent Director | 9.2yrs | US$372.55k | 0.013% $ 193.0k | |
| Independent Director | 5.8yrs | US$459.75k | 0.020% $ 292.4k | |
| Independent Director | 4.4yrs | US$365.36k | 0.013% $ 193.0k | |
| Independent Director | 9.2yrs | US$371.96k | 0.012% $ 180.0k | |
| Chairman of Scientific Advisory Board | no data | no data | 2.05% $ 30.4m | |
| Independent Director | 6.8yrs | US$365.36k | 0.013% $ 193.0k | |
| Director | less than a year | no data | no data |
7.4yrs
Average Tenure
55.5yo
Average Age
Experienced Board: KNSA's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kiniksa Pharmaceuticals International, plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Liisa Bayko | Evercore ISI |
| Paul Choi | Goldman Sachs |